Alexion Pharmaceuticals (NASDAQ:ALXN) initiated with Outperform rating and $146 (45% upside) price target at William Blair.
Change Healthcare (NASDAQ:CHNG) initiated with Buy rating and $15 (19% upside) price target at Deutsche Bank.
Denali Therapeutics (NASDAQ:DNLI) initiated with Neutral rating and $19 (10% upside) price target at Wedbush.
EXACT Sciences (NASDAQ:EXAS) initiated with Outperform rating and $130 (34% upside) price target at Oppenheimer. Shares up 1% premarket.
Interpace Diagnostics (NASDAQ:IDXG) initiated with Outperform rating and $3 (290% upside) price target at Oppenheimer. Shares up 5% premarket.
NextGen Healthcare (NASDAQ:NXGN) initiated with Hold rating and $15 (6% downside risk) price target at Deutsche Bank.
Rocket Pharmaceuticals (NASDAQ:RCKT) initiated with Overweight rating at Piper Jaffray.
Reata Pharmaceuticals (NASDAQ:RETA) initiated with Buy rating and $130 (42% upside) price target at National Securities.
Horizon Therapeutics (NASDAQ:HZNP) initiated with Buy rating and $34 (25% upside) price target at BofA Merrill Lynch. Shares up 1% premarket.
Allscripts Healthcare Solutions (NASDAQ:MDRX) initiated with Hold rating and $11 (1% upside) price target at Deutsche Bank.
AbbVie (NYSE:ABBV) upgraded to Buy with a $90 (25% upside) price target at Citigroup citing the benefits of the Allergan tie-up. Shares up 1% premarket.
Bruker (NASDAQ:BRKR) upgraded to Buy with a $52 (20% upside) price target at BofA Merrill Lynch. Shares up 2% premarket.
Hologic (NASDAQ:HOLX) upgraded to Buy with a $59 (18% upside) price target at BofA Merrill Lynch. Shares up 2% premarket.
PerkinElmer (NYSE:PKI) upgraded to Buy with a $105 (24% upside) price target at BofA Merrill Lynch.
Myriad Genetics (NASDAQ:MYGN) downgraded to Underperform with a $28 (6% downside risk) price target at BofA Merrill Lynch.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.